Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2004

01-07-2004 | Article

Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes

Authors: Y. Anis, O. Leshem, H. Reuveni, I. Wexler, R. Ben Sasson, B. Yahalom, M. Laster, I. Raz, S. Ben Sasson, E. Shafrir, E. Ziv

Published in: Diabetologia | Issue 7/2004

Login to get access

Abstract

Aims/hypothesis

G-protein-coupled receptor kinases (GRKs) play a key role in agonist-induced desensitisation of G-protein-coupled receptors (GPCRs) that are involved in metabolic regulation and glucose homeostasis. Our aim was to examine whether small peptides derived from the catalytic domain of GRK2 and -3 would ameliorate Type 2 diabetes in three separate animal models of diabetes.

Methods

Synthetic peptides derived from a kinase-substrate interaction site in GRK2/3 were initially screened for their effect on in vitro melanogenesis, a GRK-mediated process. The most effective peptides were administered intraperitoneally, utilising a variety of dosing regimens, to Psammomys obesus gerbils, Zucker diabetic fatty (ZDF) rats, or db/db mice. The metabolic effects of these peptides were assessed by measuring fasting and fed blood glucose levels and glucose tolerance.

Results

Two peptides, KRX-683107 and KRX-683124, significantly reduced fed-state blood glucose levels in the diabetic Psammomys obesus. In animals treated with KRX-683124 at a dose of 12.5 mg/kg weekly for 7 weeks, ten of eleven treated animals responded with mean blood glucose significantly lower than controls (4.7±0.4 vs 16.8±0.8 mmol/l, p≤0.0001). Significant reductions in blood glucose compared with controls were also seen in ZDF rats administered KRX-683124 and in db/db mice, which had significantly reduced fasting and 2-hour postprandial glucose levels after the treatment.

Conclusions/interpretation

Sequence-based peptides derived from GRK2/3 have an antidiabetic effect demonstrated in three different animal models of Type 2 diabetes. By modulating GRK2/3 activity, these peptides enhance GPCR-initiated signal transduction, resulting in improved glucose homeostasis. Sequence-based peptide modulation of GRK could prove useful in the treatment of Type 2 diabetes.
Literature
1.
2.
McIntyre EA, Walker M (2002) Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin Endocrinol (Oxf) 57:303–311
3.
Gloyn AL, McCarthy MI (2001) The genetics of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 15:293–308CrossRefPubMed
4.
Moneva MH, Dagogo-Jack S (2002) Multiple drug targets in the management of type 2 diabetes. Curr Drug Targets 3:203–221CrossRefPubMed
5.
6.
Crowley VE, Yeo GS, O’Rahilly S (2002) Obesity therapy: altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Discov 1:276–286CrossRefPubMed
7.
Yamada K, Ishiyama-Shigemoto S, Ichikawa F et al. (1999) Polymorphism in the 5′-leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocrinol Metab 84:1754–1757PubMed
8.
Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K (1999) Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 42:98–101CrossRefPubMed
9.
Tseng CC, Zhang XY (2000) Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling. Endocrinology 141:947–952PubMed
10.
Muzumdar R, Ma X, Yang X et al. (2003) Physiologic effect of leptin on insulin secretion is mediated mainly through central mechanisms. FASEB J 17:1130–1132PubMed
11.
Pitcher JA, Freedman NJ, Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653–692CrossRefPubMed
12.
Aragay AM, Ruiz-Gomez A, Penela P et al. (1998) G protein-coupled receptor kinase 2 (GRK2): mechanisms of regulation and physiological functions. FEBS Lett 430:37–40CrossRefPubMed
13.
Lefkowitz RJ (1996) G protein-coupled receptors and receptor kinases: from molecular biology to potential therapeutic applications. Nat Biotechnol 14:283–286CrossRefPubMed
14.
Fredericks ZL, Pitcher JA, Lefkowitz RJ (1996) Identification of the G protein-coupled receptor kinase phosphorylation sites in the human beta2-adrenergic receptor. J Biol Chem 271:13796–13803CrossRefPubMed
15.
Freedman NJ, Ament AS, Oppermann M, Stoffel RH, Exum ST, Lefkowitz RJ (1997) Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J Biol Chem 272:17734–17743CrossRefPubMed
16.
Shinyama H, Masuzaki H, Fang H, Flier JS (2003) Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization. Endocrinology 144:1301–1314CrossRefPubMed
17.
Eckhart AD, Koch WJ (2001) Transgenic studies of cardiac adrenergic receptor regulation. J Pharmacol Exp Ther 299:1–5PubMed
18.
Spurney RF, Flannery PJ, Garner SC et al. (2002) Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest 109:1361–1371CrossRefPubMedPubMedCentral
19.
Niv MY, Rubin H, Cohen J et al. (2004) Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 279:1242–1255CrossRefPubMed
20.
Briles EB, Kornfeld S (1978) Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 60:1217–1222CrossRefPubMed
21.
Shafrir E, Ziv E (1998) Cellular mechanism of nutritionally induced insulin resistance: the desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome. J Basic Clin Physiol Pharmacol 9:347–385CrossRefPubMed
22.
Kalman R, Ziv E, Shafrir E, Bar-On H, Perez R (2001) Psammomys obesus and the albino rat—two different models of nutritional insulin resistance, representing two different types of human populations. Lab Anim 35:346–352CrossRefPubMed
23.
Etgen GJ, Oldham BA (2000) Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49:684–688CrossRefPubMed
24.
Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49:22–31CrossRefPubMed
25.
Lodowski DT, Pitcher JA, Capel WD, Lefkowitz RJ, Tesmer JJ (2003) Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma. Science 300:1256–1262CrossRefPubMed
26.
Walker JK, Peppel K, Lefkowitz RJ, Caron MG, Fisher JT (1999) Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3. Am J Physiol 276:R1214–R1221PubMed
27.
Benovic JL, Mayor F Jr, Staniszewski C, Lefkowitz RJ, Caron MG (1987) Purification and characterization of the beta-adrenergic receptor kinase. J Biol Chem 262:9026–9032PubMed
28.
Rasmussen M, Almdal T, Bratholm P, Christensen NJ (2003) Elevated beta2-adrenoceptor protein concentration in adipose tissue from obese subjects is closely related to the body mass index and waist/hip ratio. Clin Sci (Lond) 104:93–102
29.
Hupfeld CJ, Dalle S, Olefsky JM (2003) Beta-Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 100:161–166CrossRefPubMed
30.
Reynisdottir S, Ellerfeldt K, Wahrenberg H, Lithell H, Arner P (1994) Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest 93:2590–2599CrossRefPubMedPubMedCentral
31.
Large V, Hellstrom L, Reynisdottir S et al. (1997) Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 100:3005–3013CrossRefPubMedPubMedCentral
32.
Ellsworth DL, Coady SA, Chen W et al. (2002) Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 26:928–937CrossRefPubMed
33.
Chang TJ, Tsai MH, Jiang YD et al. (2002) The Arg16Gly polymorphism of human beta2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people. Clin Endocrinol (Oxf) 57:685–690
34.
Joffe B, Zimmet P (1998) The thrifty genotype in type 2 diabetes: an unfinished symphony moving to its finale? Endocrine 9:139–141CrossRefPubMed
35.
Groop LC (1999) Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1 [Suppl 1]:S1–S7
36.
Goodfellow VS, Saunders J (2003) The melanocortin system and its role in obesity and cachexia. Curr Top Med Chem 3:855–883CrossRefPubMed
37.
Butler AA, Cone RD (2002) The melanocortin receptors: lessons from knockout models. Neuropeptides 36:77–84CrossRefPubMed
38.
Zaliani A, Pinori M, Ball HL, DiGregorio G, Cremonesi P, Mascagni P (1998) The interaction of myristylated peptides with the catalytic domain of protein kinase C revealed by their sequence palindromy and the identification of a myristyl binding site. Protein Eng 11:803–810CrossRefPubMed
39.
Gould C, Wong CF (2002) Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis. Pharmacol Ther 93:169–178CrossRefPubMed
40.
Licht T, Tsirulnikov L, Reuveni H, Yarnitzky T, Ben Sasson SA (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102:2099–2107CrossRefPubMed
41.
Koch WJ, Hawes BE, Inglese J, Luttrell LM, Lefkowitz RJ (1994) Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem 269:6193–6197PubMed
42.
Kadekaro AL, Kanto H, Kavanagh R, Abdel-Malek ZA (2003) Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann NY Acad Sci 994:359–365CrossRefPubMed
43.
Imokawa G, Kobayashi T, Miyagishi M, Higashi K, Yada Y (1997) The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res 10:218–228CrossRefPubMed
44.
Baig AH, Swords FM, Szaszak M, King PJ, Hunyady L, Clark AJ (2002) Agonist activated adrenocorticotropin receptor internalizes via a clathrin-mediated G protein receptor kinase dependent mechanism. Endocr Res 28:281–289CrossRefPubMed
45.
Ji S, Liu X, Li S et al. (2003) Ph domain of g protein-coupled receptor kinase-2 binds to protein kinase C (pkc) and negatively regulates activity of pkc kinase. Front Biosci 8:A34–A39CrossRefPubMed
46.
Shafrir E (2001) Albert Renold memorial lecture: molecular background of nutritionally induced insulin resistance leading to type 2 diabetes—from animal models to humans. Int J Exp Diabetes Res 2:299–319CrossRefPubMedPubMedCentral
47.
Idris I, Gray S, Donnelly R (2001) Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44:659–673CrossRefPubMed
48.
Unger RH, Orci L (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15:312–321CrossRefPubMed
49.
Hirshman MF, Fagnant PM, Horton ED, King PA, Horton ES (1995) Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle membranes. Biochem Biophys Res Commun 208:835–845CrossRefPubMed
50.
Chen H, Charlat O, Tartaglia LA et al. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491–495CrossRefPubMed
Metadata
Title
Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes
Authors
Y. Anis
O. Leshem
H. Reuveni
I. Wexler
R. Ben Sasson
B. Yahalom
M. Laster
I. Raz
S. Ben Sasson
E. Shafrir
E. Ziv
Publication date
01-07-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1444-1

Other articles of this Issue 7/2004

Diabetologia 7/2004 Go to the issue

Article

Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys

Article

Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin

Short Communication

Serum adiponectin levels predict the effect of short-term dietary interventions on insulin sensitivity in humans

For Debate

Interleukin-6 and insulin sensitivity: friend or foe?

Article

WY-14643 and 9-cis-retinoic acid induce IRS-2/PI 3-kinase signalling pathway and increase glucose transport in human skeletal muscle cells: differential effect in myotubes from healthy subjects and Type 2 diabetic patients

Article

Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin-deficient diabetes mellitus in rats
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits